Radiofrequency hyperthermia enhances the antitumor efficacy of oncolytic peptide LTX-315 in liver cancer cells by activating of cGAS-STING pathway.

Zhou G, Sun B, Zhang F, Ji H, Kan X, Yang X

International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group8 Jun 2025Cited by 3 (Europe PMC)

PMID40485182DOI10.1080/02656736.2025.2511031PepBankPUB-40485182

Publisher page PubMedAsk about this study

Jump to 10 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study10

1 result from studies that gave the peptide. No result from this study comes from people.

01AnimalOther designMechanism
In rat liver cancer experiments, LTX‑315 activated the cGAS-STING pathway.
In plain wordsIn rat cancer experiments, LTX‑315 activated an immune signaling pathway.
Peptide
LTX-315
Outcome
IncreasecGAS-STING activation
Study
Ratn: not reported in source
Hepatocellular carcinoma
Outcome group
Immune response · Cancer
Studied dose
Dose not stated
Source sentences
Summary
LTX-315 activated the cGAS-STING pathway, with RFH further enhancing this activation.
2 context sentences(design, population, supporting numbers)
Summary · context
In vitro experiments using rat hepatocellular carcinoma (HCC) cells and in vivo experiments with HCC rat models were conducted.
Summary · context
Treatments included (1) phosphate buffered saline, (2) RFH at 42 °C for 30 min, (3) LTX-315 alone, and (4) a combination of RFH with LTX-315.
Report a problemFND-4048518205

Studies that did not test the peptide alone9

In this study, LTX-315 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking LTX-315.

02AnimalNot a test of LTX-315 aloneAnimal study (in vivo)Efficacy outcome
In rats with liver cancer, RFH plus LTX‑315 produced the smallest tumor volume compared with other groups.
In plain wordsIn rats, RFH plus LTX‑315 produced the smallest tumors compared with other groups.
Peptide
LTX-315
Outcome
DecreaseTumor volume
Study
Ratn: not reported in source
Hepatocellular carcinoma
Comparator
Other groups
Outcome group
Tumor growth · Cancer
Source sentences
Summary
The combination treatment (RFH + LTX-315) resulted in the highest level of apoptosis and the lowest cell viability, along with the smallest tumor volume and strongest reduction in bioluminescence signal compared to other groups (p < 0.001).
2 context sentences(design, population, supporting numbers)
Summary · context
In vitro experiments using rat hepatocellular carcinoma (HCC) cells and in vivo experiments with HCC rat models were conducted.
Summary · context
Treatments included (1) phosphate buffered saline, (2) RFH at 42 °C for 30 min, (3) LTX-315 alone, and (4) a combination of RFH with LTX-315.
In this study, LTX-315 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking LTX-315.
Report a problemFND-4048518203
03AnimalNot a test of LTX-315 aloneAnimal study (in vivo)Efficacy outcome
In rats with liver cancer, RFH plus LTX‑315 produced the strongest bioluminescence signal reduction compared with other groups.
In plain wordsIn rats, RFH plus LTX‑315 reduced the tumor light signal most compared with other groups.
Peptide
LTX-315
Outcome
DecreaseBioluminescence signal
Study
Ratn: not reported in source
Hepatocellular carcinoma
Comparator
Other groups
Outcome group
Tumor growth · Cancer
Source sentences
Summary
The combination treatment (RFH + LTX-315) resulted in the highest level of apoptosis and the lowest cell viability, along with the smallest tumor volume and strongest reduction in bioluminescence signal compared to other groups (p < 0.001).
2 context sentences(design, population, supporting numbers)
Summary · context
In vitro experiments using rat hepatocellular carcinoma (HCC) cells and in vivo experiments with HCC rat models were conducted.
Summary · context
Treatments included (1) phosphate buffered saline, (2) RFH at 42 °C for 30 min, (3) LTX-315 alone, and (4) a combination of RFH with LTX-315.
In this study, LTX-315 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking LTX-315.
Report a problemFND-4048518204
04AnimalNot a test of LTX-315 aloneAnimal study (in vivo)Mechanism
In rat tumors, RFH plus LTX‑315 significantly increased CD8 T cells.
In plain wordsIn rats, RFH plus LTX‑315 increased CD8 T cells in tumors.
Peptide
LTX-315
Outcome
IncreaseCD8 T cells
Study
Ratn: not reported in source
Hepatocellular carcinoma
Outcome group
Immune response · Cancer
Source sentences
Summary
After combination therapy, significant increases in CD8+ T cells, CD8+/IFN-γ+ T cells, CD8+/TNF-α+ T cells, and natural killer cells, along with a decrease in Tregs, were observed in tumors (p < 0.001).
2 context sentences(design, population, supporting numbers)
Summary · context
In vitro experiments using rat hepatocellular carcinoma (HCC) cells and in vivo experiments with HCC rat models were conducted.
Summary · context
Treatments included (1) phosphate buffered saline, (2) RFH at 42 °C for 30 min, (3) LTX-315 alone, and (4) a combination of RFH with LTX-315.
In this study, LTX-315 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking LTX-315.
Report a problemFND-4048518206
05AnimalNot a test of LTX-315 aloneAnimal study (in vivo)Mechanism
In rat tumors, RFH plus LTX‑315 significantly increased CD8/IFN-gamma T cells.
In plain wordsIn rats, RFH plus LTX‑315 increased interferon-producing CD8 T cells in tumors.
Peptide
LTX-315
Outcome
IncreaseCD8/IFN-gamma T cells
Study
Ratn: not reported in source
Hepatocellular carcinoma
Outcome group
Immune response · Cancer
Source sentences
Summary
After combination therapy, significant increases in CD8+ T cells, CD8+/IFN-γ+ T cells, CD8+/TNF-α+ T cells, and natural killer cells, along with a decrease in Tregs, were observed in tumors (p < 0.001).
2 context sentences(design, population, supporting numbers)
Summary · context
In vitro experiments using rat hepatocellular carcinoma (HCC) cells and in vivo experiments with HCC rat models were conducted.
Summary · context
Treatments included (1) phosphate buffered saline, (2) RFH at 42 °C for 30 min, (3) LTX-315 alone, and (4) a combination of RFH with LTX-315.
In this study, LTX-315 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking LTX-315.
Report a problemFND-4048518207
06AnimalNot a test of LTX-315 aloneAnimal study (in vivo)Mechanism
In rat tumors, RFH plus LTX‑315 significantly increased CD8/TNF-alpha T cells.
In plain wordsIn rats, RFH plus LTX‑315 increased TNF-producing CD8 T cells in tumors.
Peptide
LTX-315
Outcome
IncreaseCD8/TNF-alpha T cells
Study
Ratn: not reported in source
Hepatocellular carcinoma
Outcome group
Immune response · Cancer
Source sentences
Summary
After combination therapy, significant increases in CD8+ T cells, CD8+/IFN-γ+ T cells, CD8+/TNF-α+ T cells, and natural killer cells, along with a decrease in Tregs, were observed in tumors (p < 0.001).
2 context sentences(design, population, supporting numbers)
Summary · context
In vitro experiments using rat hepatocellular carcinoma (HCC) cells and in vivo experiments with HCC rat models were conducted.
Summary · context
Treatments included (1) phosphate buffered saline, (2) RFH at 42 °C for 30 min, (3) LTX-315 alone, and (4) a combination of RFH with LTX-315.
In this study, LTX-315 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking LTX-315.
Report a problemFND-4048518208
07AnimalNot a test of LTX-315 aloneAnimal study (in vivo)Mechanism
In rat tumors, RFH plus LTX‑315 significantly increased natural killer cells.
In plain wordsIn rats, RFH plus LTX‑315 increased natural killer cells in tumors.
Peptide
LTX-315
Outcome
IncreaseNatural killer cells
Study
Ratn: not reported in source
Hepatocellular carcinoma
Outcome group
Immune response · Cancer
Source sentences
Summary
After combination therapy, significant increases in CD8+ T cells, CD8+/IFN-γ+ T cells, CD8+/TNF-α+ T cells, and natural killer cells, along with a decrease in Tregs, were observed in tumors (p < 0.001).
2 context sentences(design, population, supporting numbers)
Summary · context
In vitro experiments using rat hepatocellular carcinoma (HCC) cells and in vivo experiments with HCC rat models were conducted.
Summary · context
Treatments included (1) phosphate buffered saline, (2) RFH at 42 °C for 30 min, (3) LTX-315 alone, and (4) a combination of RFH with LTX-315.
In this study, LTX-315 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking LTX-315.
Report a problemFND-4048518209
08AnimalNot a test of LTX-315 aloneAnimal study (in vivo)Mechanism
In rat tumors, RFH plus LTX‑315 decreased regulatory T cells.
In plain wordsIn rats, RFH plus LTX‑315 reduced regulatory T cells in tumors.
Peptide
LTX-315
Outcome
DecreaseRegulatory T cells
Study
Ratn: not reported in source
Hepatocellular carcinoma
Outcome group
Immune response · Cancer
Source sentences
Summary
After combination therapy, significant increases in CD8+ T cells, CD8+/IFN-γ+ T cells, CD8+/TNF-α+ T cells, and natural killer cells, along with a decrease in Tregs, were observed in tumors (p < 0.001).
2 context sentences(design, population, supporting numbers)
Summary · context
In vitro experiments using rat hepatocellular carcinoma (HCC) cells and in vivo experiments with HCC rat models were conducted.
Summary · context
Treatments included (1) phosphate buffered saline, (2) RFH at 42 °C for 30 min, (3) LTX-315 alone, and (4) a combination of RFH with LTX-315.
In this study, LTX-315 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking LTX-315.
Report a problemFND-4048518210
09LabNot a test of LTX-315 aloneIn vitro (cells)Mechanism
In rat liver cancer cells, RFH plus LTX‑315 produced the highest apoptosis compared with other groups.
In plain wordsIn cells, RFH plus LTX‑315 produced the most cell death compared with other groups.
Peptide
LTX-315
Outcome
IncreaseApoptosis
Study
Ratn: not reported in source
Hepatocellular carcinoma
Comparator
Other groups
Outcome group
Receptor activity and mechanism · Cancer
Source sentences
Summary
The combination treatment (RFH + LTX-315) resulted in the highest level of apoptosis and the lowest cell viability, along with the smallest tumor volume and strongest reduction in bioluminescence signal compared to other groups (p < 0.001).
2 context sentences(design, population, supporting numbers)
Summary · context
In vitro experiments using rat hepatocellular carcinoma (HCC) cells and in vivo experiments with HCC rat models were conducted.
Summary · context
Treatments included (1) phosphate buffered saline, (2) RFH at 42 °C for 30 min, (3) LTX-315 alone, and (4) a combination of RFH with LTX-315.
In this study, LTX-315 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking LTX-315.
Report a problemFND-4048518201
10LabNot a test of LTX-315 aloneIn vitro (cells)Efficacy outcome
In rat liver cancer cells, RFH plus LTX‑315 produced the lowest viability compared with other groups.
In plain wordsIn cells, RFH plus LTX‑315 produced the lowest viability compared with other groups.
Peptide
LTX-315
Outcome
DecreaseCell viability
Study
Ratn: not reported in source
Hepatocellular carcinoma
Comparator
Other groups
Outcome group
Tumor growth · Cancer
Source sentences
Summary
The combination treatment (RFH + LTX-315) resulted in the highest level of apoptosis and the lowest cell viability, along with the smallest tumor volume and strongest reduction in bioluminescence signal compared to other groups (p < 0.001).
2 context sentences(design, population, supporting numbers)
Summary · context
In vitro experiments using rat hepatocellular carcinoma (HCC) cells and in vivo experiments with HCC rat models were conducted.
Summary · context
Treatments included (1) phosphate buffered saline, (2) RFH at 42 °C for 30 min, (3) LTX-315 alone, and (4) a combination of RFH with LTX-315.
In this study, LTX-315 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking LTX-315.
Report a problemFND-4048518202

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
27 Oct 2026, 18:20 UTC
Study results updated
Version 1
27 Oct 2026, 16:32 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Journal Article

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.